Literature DB >> 12490392

Characterization of the human cytomegalovirus UL75 (glycoprotein H) late gene promoter.

Bernard J P McWatters1, Richard M Stenberg, Julie A Kerry.   

Abstract

Glycoprotein H (gH, UL75) of human cytomegalovirus (HCMV) is an essential envelope glycoprotein that functions in viral entry and the activation of gene expression. To understand the regulation of this important viral gene, the promoter of the UL75 late gene was characterized in HCMV-infected cells at the late stages of viral infection. Primer extension analysis revealed a single major start site located 26 bp downstream of a putative TATA element. Deletion analysis showed the presence of a dominant activation domain from +14 to +35 that masked regulatory sequences upstream of the TATA element. Mutational analysis demonstrated that a PEA3-like element in this downstream domain was important for promoter activation. In addition, gel shift analysis revealed direct protein binding to the PEA3-like element. Together, these studies reveal that the gH promoter is regulated in a complex manner with sequences both upstream and downstream of the cap site influencing promoter activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490392     DOI: 10.1006/viro.2002.1614

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  The late promoter of the human cytomegalovirus viral DNA polymerase processivity factor has an impact on delayed early and late viral gene products but not on viral DNA synthesis.

Authors:  Hiroki Isomura; Mark F Stinski; Ayumi Kudoh; Sanae Nakayama; Satoko Iwahori; Yoshitaka Sato; Tatsuya Tsurumi
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

2.  Cytomegalovirus UL91 is essential for transcription of viral true late (γ2) genes.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

3.  Transcription of true late (γ2) cytomegalovirus genes requires UL92 function that is conserved among beta- and gammaherpesviruses.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

4.  Nucleocytoplasmic shuttling of human cytomegalovirus UL84 is essential for virus growth.

Authors:  Yang Gao; Dominique Kagele; Kate Smallenberg; Gregory S Pari
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

5.  Construction of a full transcription map of human papillomavirus type 18 during productive viral infection.

Authors:  Xiaohong Wang; Craig Meyers; Hsu-Kun Wang; Louise T Chow; Zhi-Ming Zheng
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

6.  The human cytomegalovirus gene products essential for late viral gene expression assemble into prereplication complexes before viral DNA replication.

Authors:  Hiroki Isomura; Mark F Stinski; Takayuki Murata; Yoriko Yamashita; Teru Kanda; Shinya Toyokuni; Tatsuya Tsurumi
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

7.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Murine cytomegalovirus protein pM79 is a key regulator for viral late transcription.

Authors:  Travis J Chapa; L Steven Johnson; Christopher Affolter; Mark C Valentine; Anthony R Fehr; Wayne M Yokoyama; Dong Yu
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

9.  Requirement of a 12-base-pair TATT-containing sequence and viral lytic DNA replication in activation of the Kaposi's sarcoma-associated herpesvirus K8.1 late promoter.

Authors:  Shuang Tang; Koji Yamanegi; Zhi-Ming Zheng
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Human cytomegalovirus UL84 insertion mutant defective for viral DNA synthesis and growth.

Authors:  Yiyang Xu; Sylvia A Cei; Alicia Rodriguez Huete; Gregory S Pari
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.